Synergistic Anti-inflammatory and Osteogenic N-HA/resveratrol/chitosan Composite Microspheres for Osteoporotic Bone Regeneration
Overview
Affiliations
The development of functional materials for osteoporosis is ultimately required for bone remodeling. However, grafts were accompanied by increasing pro-inflammatory cytokines that impaired bone formation. In this work, nano-hydroxyapatite (n-HA)/resveratrol (Res)/chitosan (CS) composite microspheres were designed to create a beneficial microenvironment and help improve the osteogenesis by local sustained release of Res. Study of release confirmed the feasibility of n-HA/Res/CS microspheres for controlled Res release. Notably, microspheres had anti-inflammatory activity evidenced by the decreased expression of pro-inflammatory cytokines TNF-α, IL-1β and iNOS in RAW264.7 cells in a dose dependent manner. Further, enhanced adhesion and proliferation of BMSCs seeded onto microspheres demonstrated that composite microspheres were conducive to cell growth. The ability to enhance osteo-differentiation was supported by up-regulation of Runx2, ALP, Col-1 and OCN, and substantial mineralization in osteogenic medium. When implanted into bone defects in the osteoporotic rat femoral condyles, enhanced entochondrostosis and bone regeneration suggested that the n-HA/Res/CS composite microspheres were more favorable for impaired fracture healing. The results indicated that optimized n-HA/Res/CS composite microspheres could serve as promising multifunctional fillers for osteoporotic bone defect/fracture treatment.
Sun T, Ma D, Song Y, Hu J, Yang Z, Wang X J Int Med Res. 2025; 53(2):3000605251315024.
PMID: 39932304 PMC: 11815949. DOI: 10.1177/03000605251315024.
Tissue Mimetic Membranes for Healing Augmentation of Tendon-Bone Interface in Rotator Cuff Repair.
Zhu Y, Dai B, Zhang S, Liu J, Xu S, Liu W Adv Mater. 2025; 37(10):e2407358.
PMID: 39888084 PMC: 11899491. DOI: 10.1002/adma.202407358.
Li P, Chen S, Meng Y, Wang C, Ni X ACS Omega. 2024; 9(50):49043-49053.
PMID: 39713622 PMC: 11656249. DOI: 10.1021/acsomega.4c02849.
Zheng Y, Wang Y, Sheng F, Wang S, Zhou Y, Li X Front Pharmacol. 2024; 15:1499742.
PMID: 39588147 PMC: 11586164. DOI: 10.3389/fphar.2024.1499742.
Shan J, Yu Y, Liu X, Chai Y, Wang X, Wen G Heliyon. 2024; 10(19):e37431.
PMID: 39381099 PMC: 11456830. DOI: 10.1016/j.heliyon.2024.e37431.